1 - Active clinical study - Recruitment ongoing***
15-ONCO-01***
Lymphoma
Objective
To assess the efficacy and safety of a treatment in combination with corticosteroid in lymphoma
Main criteria
Multicentric, B or T lymphoma (naïve dogs / first relapse)
Administration
Palliative treatment – orally
Treatment duration
3 months + Prednisolone throughout life
Evaluation
Lymph nodes measurement & clinical
2 - Active clinical study - Recruitment ongoing**
16-ONCO-02**
Lymphoma
Objective
To assess the efficacy and safety of a combination of treatments on spontaneous non-surgical malignant tumors
Main criteria
Multicentric high grade B or T lymphoma (naïve dogs / relapse)
Administration
Orally
Treatment duration
56 days
Evaluation
CT-scan & clinical
3 - Active clinical study - Recruitment ongoing*
16-ONCO-03*
Lymphoma
Objectif
To assess the efficacy of a therapeutic vaccine on malignant tumors
Main criteria
Diffuse large B cells lymphoma with full or partial recovery after a chemotherapy regimen
Administration
Intradermal vaccine
Treatment duration
3 to 12 months
Evaluation
Lymph nodes measurement, clinical, X-ray & ultrasound
1 - Active clinical study - Recruitment ongoing**
16-ONCO-02**
Osteosarcoma with measurable metastasis
Objective
To assess the efficacy and safety of a combination of treatments on spontaneous non-surgical malignant tumors
Main criteria
Unresectable tumor metastasis measurable at CT-scan
Administration
Orally
Treatment duration
56 days
Evaluation
CT-scan & clinical
1 - Active clinical study - Recruitment ongoing*
16-ONCO-01*
Soft tissue Sarcoma
Objective
To assess clinical efficacy of an oncolytic virus in combination with a treatment on inoperable malignant tumors
Main criteria
Tumor accessible to intra-tumoral injections
Administration
Vaccine & oral treatment
Treatment duration
12 weeks
Evaluation
CT-scan & clinical
2 - Active clinical study - Recruitment ongoing**
16-ONCO-02**
High grade soft tissue Sarcoma
Objective
To assess the efficacy and safety of a combination of treatments on spontaneous non-surgical malignant tumors
Main criteria
Unresectable tumor measurable at CT-scan
Administration
Orally
Treatment duration
56 days
Evaluation
CT-scan & clinical
1 - Active clinical study - Recruitment ongoing*
16-ONCO-01*
Malignant oral or cutaneous Melanoma
Objective
To assess clinical efficacy of an oncolytic virus in combination with a treatment on inoperable malignant tumors
Main criteria
Tumor accessible to intra-tumoral injections
Administration
Vaccine & oral treatment
Treatment duration
12 weeks
Evaluation
CT-scan & clinical
2 - Active clinical study - Recruitment ongoing*
16-ONCO-05*
Oral Melanoma
Objective
To assess the efficacy of a therapeutic vaccine on malignant tumors
Main criteria
Melanoma of stage I, II or III operated or not
Administration
Intradermal vaccine & radiotherapy
Treatment duration
3 to 12 months
Evaluation
CT-scan & clinical
1 - Active clinical study - Recruitment ongoing**
16-ONCO-02**
High grade mammary Carcinoma
Objective
To assess the efficacy and safety of a combination of treatments on spontaneous non-surgical malignant tumors
Main criteria
Unresectable tumor measurable at CT-scan
Administration
Orally
Treatment duration
56 days
Evaluation
CT-scan & clinical
1 - Active clinical study - Recruitment ongoing*
16-ONCO-01*
Malignant non-surgical tumors
Objective
To assess clinical efficacy of an oncolytic virus in combination with a treatment on inoperable malignant tumors
Main criteria
Tumor accessible to intra-tumoral injections: mammary carcinoma, prostatic carcinoma, head & neck carcinoma, or rectal
Administration
Vaccine & oral treatment
Treatment duration
12 weeks
Evaluation
CT-scan & clinical
1 - Active clinical study - Recruitment ongoing***
17-ONCO-01***
Progressive malignant tumors
(solid tumors)
Objective
To assess the immunomodulating action
of a food supplement (phytotherapy)
on dogs suffering from progressive
malignant tumors
Main criteria
Solid tumors (all types)
operated or not, with or without metastasis
Administration
Per os
Treatment duration
49 days
Evaluation
Biological & quality of life
*Single site study : Case to refer to ONCOVET clinic (59)
**Multicentric study : Participating centres : ONCOVET (59) – CHV POMMERY (51) – ALLIANCE (33) – FM Liège (4000, Belgique) – EIFFELVET (75) – CHV FRÉGIS (94)
***Multicentric study : Please contact us to be informed about list of sites involved in the study
OCR – Parc Eurasanté, Lille Métropole – 80 Rue du Docteur Yersin, 59120 LOOS – FRANCE
+33 (0)3 20 56 82 93 – contact@oncovet-clinical-research.com – www.oncovet-clinical-research.com
